Skip to Content
Merck
CN
  • Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.

Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.

Journal of neuro-oncology (2016-11-07)
C Kurokawa, H Geekiyanage, C Allen, I Iankov, M Schroeder, B Carlson, K Bakken, J Sarkaria, J A Ecsedy, A D'Assoro, B Friday, E Galanis
PMID27816996
ABSTRACT

Aurora A kinase (AURKA), a member of the serine/threonine kinase family, plays a critical role in cell division, and it is widely overexpressed in a variety of tumors including glioblastoma (GBM). Alisertib (MLN8237) is an orally administered selective AURKA inhibitor with potent antiproliferative activity, currently undergoing clinical testing in different tumor types. In vitro evaluation of alisertib against the primary GBM lines, GBM6, GBM10, GBM12 and GBM39 showed significant antitumor activity with IC